Gaiesville, Florida -- Life sciences company Quick-Med Technologies Inc. says the patent office of Mexico has issued it with patent No. 297 242, "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate," with similar patents granted in the US, Australia, and South Africa and pending in Canada, China, Europe, India, and Japan.
The patent covers the method of production that non-leachably bonds Nimbus antimicrobials to substrates including polyurethane, cellulosic or substrates including polyester, nylon and acrylics, silk, linen, rubber, alginates and collagen. These materials are commonly used in textile and medical products, filters, absorbent products, and packaging.
"Our non-leachable bonding of the antimicrobial agent distinguishes Nimbus from other antimicrobial materials which require release of the active agent in order to function," said Dr Jerry Olderman, Quick-Med's vice president of research & development, in a company announcement. "This patent covers the process of treating materials such that they become permanent barriers to the transmission of microorganisms."
Nimbus antimicrobials remain at full strength, but the active agent in most other antimicrobial technologies is depleted gradually while in use. Other antimicrobials also carry the risk of irritation or interference with healing in products such as wound dressings and textile applications in which the treated material is next to or used on the skin.
Quick-Med says the bonding of an antimicrobial to a substrate is "a paradigm shift" from the current approach which fosters release of the active agent. The value of a non-leaching antimicrobial is that it does not allow depletion of the active agent which can lead to damage to human skin or tissue cells such that they can cause irritation, delay healing and possibly initiate the development of bacterial resistance